Athens University Medical School, Hippokration Hospital,Vasilissis Sofias 114, 115 28, Athens, Greece.
Blood Rev. 2011 Nov;25(6):239-45. doi: 10.1016/j.blre.2011.05.001. Epub 2011 Jun 8.
Several prospective epidemiological studies and clinical observations provided evidence regarding fibrinogen and coronary artery disease (CAD). Many of these studies firmly correlate fibrinogen with CAD. However, it is uncertain whether this relation is causal or reflects genetic variability and residual confounding by other risk factors. Several polymorphisms on fibrinogen chain genes affect its levels, however only few of the genetic variants are associated with increased cardiovascular risk. As regards the role of fibrinogen in myocardial infarction (MI) studies indicate that genetic variations have at best a modest impact on the process resulting in MI. Therefore, the screening of fibrinogen genes might not be useful for the assessment of the risk of MI. However, the findings that specific genotypes lead to specific differences in fibrinogen levels, but may not be linked to cardiovascular risk, complicates the hypothesis of causality of fibrinogen in the pathogenesis of cardiovascular disease.
几项前瞻性流行病学研究和临床观察为纤维蛋白原与冠状动脉疾病(CAD)之间的关系提供了证据。这些研究中有许多将纤维蛋白原与 CAD 紧密相关联。然而,尚不确定这种关系是因果关系还是反映了遗传变异性和其他危险因素的残余混杂。纤维蛋白原链基因上的几种多态性会影响其水平,但只有少数遗传变异与心血管风险增加相关。至于纤维蛋白原在心肌梗死(MI)中的作用,研究表明遗传变异对导致 MI 的过程的影响充其量只是适度的。因此,纤维蛋白原基因的筛查可能对评估 MI 的风险没有用处。然而,特定基因型导致纤维蛋白原水平的特定差异,但可能与心血管风险无关,这使纤维蛋白原在心血管疾病发病机制中的因果关系假设变得复杂。